Sequenom Scores on Down Syndrome Detection
Sequenom, Inc. (NASDAQ: SQNM) is having a major trading response to its Down Syndrome testing news. The genetic-analysis and molecular diagnostic solutions provider gave additional positive results from screening studies on its noninvasive circulating cell-free fetal nucleic acid SEQureDx™ Technology.
This is to enable the detection of fetal aneuploidy, including Down syndrome from maternal blood. The presentation is from its Sequenom’s analyst briefing in New York City.
Sequenom’s test demonstrated no false positives and no false negatives in both first and second trimester samples. Over 200 samples were announced today and this is now in excess of 400 prospective samples to-date. Sequenom executives were joined by a panel of leading scientists and clinicians to discuss these study results and updates in the development of noninvasive prenatal diagnostics.
With the abundance of women having children later and later in life, Down Syndrome testing is going to be more important than ever. In fact, it could be front and center after the election as VP-candidate Palin’s family is affected by this.
Jon Ogg
September 24, 2008